T cell, mouse, stim

lymphocyte isolated from mouse spleen; pre-stimulated

Cell Type:
T Cell
Tissue Origin:
blood
Species:
mouse
Research Area:
Cancer Research/Cell Biology
Immunotherapy / Hematology
Cell Characteristics:
Suspension

Recommended Media

X-VIVO Serum-free Hematopoietic Cell Media provide nutritionally complete and balanced environments for a variety of cells including lymphokine activated killer (LAK) cells, peripheral blood lymphocytes (PBL), and tumor infiltrating lymphocytes (TIL).These media do not contain any exogenous growth factors, artificial stimulators of cellular proliferation, or undefined supplements. They are devoid of any protein kinase C stimulators and are suitable for the investigation of second messenger systems in the activation of human and murine lymphocytes.

There are three versions of this media:

  • X-VIVO 10  - designed to support the generation of LAK cells in a serum-free environment.
  • X-VIVO 15 - similar in composition to X-VIVO 10 but optimized for the proliferation of tumor infiltrating lymphocytes (TIL) under serum-free conditions. It also supports the proliferation of purified CD3+ cells isolated from peripheral blood and human tumors, and can be used to support the growth of human monocytes, macrophage cells and cell lines, PBL, granulocytes, and natural killer (NK) cells as well as the expansion of HUT-78 and related human lymphocytic cell lines.
  • X-VIVO 20 - optimized to support the generation of lymphokine activated killer (LAK) cells from monocyte depleted peripheral blood lymphocytes (PBL) at high density and has also been used as a growth medium for PBL and tumor infiltrating lymphocytes (TIL).

Storage = 2ºC to 8ºC

04-380Q - X-VIVO 10 with L-glutamine, gentamicin and phenol red
04-743Q - X-VIVO 10 with L-glutamine, but without gentamicin or phenol red
04-418 - X-VIVO 15  with L-glutamine, gentamicin and phenol red
04-744Q - X-VIVO 15 with L-glutamine, but without gentamicin or phenol red
04-448Q - X-VIVO 20  with L-glutamine, gentamicin and phenol red

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
Filter:
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
P3 DN-100 2e5 77% 33% Plasmid (general) 0.4 µg 20 µl 4D X-Unit

Citations (17)

Categories:
Primary Cells and Media, Transfection 
Authors:
Nyberg WA, Ark J, To A, Clouden S, Reeder G, Muldoon JJ, Chung JY, Xie WH, Allain V, Steinhart Z, Chang C, Talbot A, Kim S, Rosales A, Havlik LP, Pimentel H, Asokan A, Eyquem J 
In:
Cell (2023) 186(2): 446-460 
Categories:
Transfection, Cell Lines and Primary Cancer Cells 
Authors:
Pfenninger P, Yerly L, Abe J 
In:
Frontiers in Immunology (2022) 13: 777113 
Categories:
Transfection 
Authors:
Giuffrida L, Sek K, Henderson MA, Lai J, Chen AXY, Meyran D, Todd KL, Petley EV, Mardiana S, Mølck C, Stewart GD, Solomon BJ, Parish IA, Neeson PJ, Harrison SJ, Kats LM, House IG, Darcy PK, Beavis PA 
In:
Nat Commun. (2021) 12(1): 3236 
Categories:
Serum-free and Speciality Media 
Authors:
Ann-Helen Willrodt, Ann-Charlott Salabarria, Philipp Schineis, Desislava Ignatova,Morgan Campbell Hunter, Martina Vranova, Alexandra M. Golding-Ochsenbein,Elena Sigmund, Annatina Romagna, Verena Strassberger, Marina Fabbi,Silvano Ferrini , Claus Cursiefen, Dario Neri, Emmanuella Guenova, Felix Bock andCornelia Halin 
In:
Frontiers in Immunology (2019) 10: 759 
Categories:
Primary Cells and Media, Transfection 
Authors:
Oh SA, Seki A, Rutz S.  
In:
Curr Protoc Immunol (2019) 124(1): e69 
Categories:
Primary Cells and Media, Transfection 
Authors:
Ito M, Komai K, Mise-Omata S, Iizuka-Koga M, Noguchi Y, Kondo T, Sakai R, Matsuo K, Nakayama T, Yoshie O, Nakatsukasa H, Chikuma S, Shichita T, Yoshimura A. 
In:
Nature (2019) 565 (7738): 246-250 
Categories:
Primary Cells and Media, Transfection 
Authors:
Seki A, Rutz S. 
In:
J Exp Med (2018) 215(3): 985-997 
Categories:
Serum-free and Speciality Media 
Authors:
Fitzgerald DC, O'Brien K, Young A, Fonseca-Kelly Z, Rostami A, Gran B. 
In:
Journal of Neuroinflammation (2014) 11: 130 
Categories:
Transfection 
Authors:
Yao C1, Hirata T, Soontrapa K, Ma X, Takemori H, Narumiya S. 
In:
Nat Commun. (2013) 4: 1685 
Categories:
Serum-free and Speciality Media 
Authors:
Tibor T. Glant, Marianna Radacs, Gyorgy Nagyeri, Katalin Olasz, Anna Laszlo, Ferenc Boldizsar, Akos Hegyi, Alison Finnegan, and Katalin Mikecz  
In:
Rheumatology (2011) 63: 5 
Categories:
Transfection 
Authors:
Chung JS, Dougherty I, Cruz PD Jr, Ariizumi K 
In:
J Immunol (2007) 179(9): 5778-84 
Categories:
Transfection 
Authors:
Schoenborn JR, Dorschner MO, Sekimata M, Santer DM, Shnyreva M, Fitzpatrick DR, Stamatoyonnapoulos JA, Wilson CB 
In:
Nat Immunol (2007) 8(7): 732-42 
Categories:
Transfection 
Authors:
Sasaki K, Zhu X, Vasquez C, Nishimura F, Dusak JE, Huang J, Fujita M, Wesa A, Potter DM, Walker PR, Storkus WJ, Okada H 
In:
Cancer Res (2007) 67(13): 6451-8 
Categories:
Transfection 
Authors:
Mor A, Campi G, Du G, Zheng Y, Foster DA, Dustin ML, Philips MR 
In:
Nat Cell Biol (2007) 9(6): 713-9 
Categories:
Transfection 
Authors:
Hosokawa H, Kimura MY, Shinnakasu R, Suzuki A, Miki T, Koseki H, van Lohuizen M, Yamashita M, Nakayama T 
In:
J Immunol (2006) 177(11): 7656-64 
Categories:
Transfection 
Authors:
Singh N, Seki Y, Takami M, Baban B, Chandler PR, Khosravi D, Zheng X, Takezaki M, Lee JR, Mellor AL, Bollag WB, Iwashima M 
In:
Nat Methods (2006) 3(8): 629-36 
Categories:
Transfection 
Authors:
Goffinet C and Keppler OT 
In:
FASEB J (2006) 20(3): 500-2 
+ Show All